Echinocystic acid inhibits the growth of human bladder cancer cells by suppressing AKT1/GSKβ/β-Catenin signaling and synergizes with gemcitabine.

Xueqian Han, Liping Xie, Ziyun Li, Yajun Hou, Yunfeng He, Liqiong He, Jinyong Luo

Abstract read

In one paragraph

Article in Genes & diseases, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xueqian HanCollege of Laboratory Medicine, Chongqing Medical University, Key Laboratory of Clinical Laboratory Diagnostics (Chinese Ministry of Education), Chongqing 400016, China.

Liping XieCollege of Laboratory Medicine, Chongqing Medical University, Key Laboratory of Clinical Laboratory Diagnostics (Chinese Ministry of Education), Chongqing 400016, China.

Ziyun LiCollege of Laboratory Medicine, Chongqing Medical University, Key Laboratory of Clinical Laboratory Diagnostics (Chinese Ministry of Education), Chongqing 400016, China.

Yajun HouCollege of Laboratory Medicine, Chongqing Medical University, Key Laboratory of Clinical Laboratory Diagnostics (Chinese Ministry of Education), Chongqing 400016, China.

Yunfeng HeDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Liqiong HeDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Jinyong LuoCollege of Laboratory Medicine, Chongqing Medical University, Key Laboratory of Clinical Laboratory Diagnostics (Chinese Ministry of Education), Chongqing 400016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer (BC) is an aggressive and treatment-resistant malignancy with a high recurrence rate. Current first-line therapies only provide limited relief due to chemoresistance and toxicity. Natural products are emerging as promising chemotherapeutic agents due to their multi-target mechanisms and excellent safety profile. In this study, we evaluated the anti-BC effects of echinocystic acid (EA), a pentacyclic triterpenoid, on BC cells and investigated the underlying mechanism. We found that EA effectively inhibited proliferation, triggered G1-phase cell cycle arrest, and simultaneously suppressed cellular invasion and migration capabilities

Indexed as

AKT1Bladder cancerEchinocystic acidFerroptosisNatural product

Identifiers

PMID42898456

DOI10.1016/j.gendis.2026.102148

PMCPMC13677775

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.